GenVec will collaborate with Novartis AG (NVS) in developing treatments for hearing loss and balance disorders, saying it could receive as much as $213.6 million in upfront and milestone payments from the partnership. GenVec's shares jumped 20% to $2.08
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.